ClinicalTrialsFinder
RecruitingPhase 1NCT07283770

Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants

A Phase 1, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study Evaluating Safety and Pharmacokinetics of VX-581 in Healthy Subjects

Sponsor

Vertex Pharmaceuticals Incorporated

Enrollment

128 participants

Start Date

Dec 9, 2025

Study Type

INTERVENTIONAL

Conditions

Cystic Fibrosis

Summary

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending doses of VX-581.

Eligibility

Min Age: 18 YearsMax Age: 55 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Placebo and a drug called VX-581 for people with cystic fibrosis. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 55 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGVX-581

Suspension for Oral Administration.

DRUGPlacebo

Suspension for Oral Administration.

Locations(1)

Altasciences - Kansas City

Overland Park, Kansas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07283770

Related Trials

Role of Genetic Factors in the Development of Lung Disease

NCT000015322 locations

FEED-Cystic Fibrosis (FEED-CF)

NCT057667741 location

Natural History of Noncirrhotic Portal Hypertension

NCT024177401 location

Rare CFTR Mutation Cell Collection Protocol (RARE)

NCT031618081 location

Correction of Nonsense Mutations in Cystic Fibrosis

NCT036704728 locations